TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Key Inclusion Criteria include:~1. Males and females ≥18 years of age~2. An estimated glomerular filtration rate \<60 mL/minute or a diagnosis of CKD (such as nephropathy, nephritis)~3. Hemoglobin \<11.0 g/deciliter (dL)~4. Transferrin saturation \<30%~5. Hemodialysis participants on maintenance dialysis for at least 3 months prior to screening and currently receiving dialysis 3 times per week~6. Female participants of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening and agree to remain on birth control until completion of the study~Exclusion Criteria:~Key Exclusion Criteria include:~1. History of allergy to IV iron~2. Allergy to 2 or more classes of drugs~3. Female participants who are pregnant or intend to become pregnant, breastfeeding, within 3 months postpartum, or have a positive serum or urine pregnancy test~4. Hemoglobin ≤7.0 g/dL~5. Received another investigational agent within 4 weeks prior to screening, or planned receipt of an unspecified investigational agent during the study period~6. Known causes of anemia other than iron deficiency (such as hemolysis and vitamin B12 or folate deficiency)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferumoxytol (Type: EXPERIMENTAL): Participants received an IV injection of ferumoxytol (510 milligrams \[mg\], 17 milliliters \[mL\]) on Day 1 (Baseline). This was followed by a second injection of ferumoxytol (510 mg, 17 mL) 5±3 days later for a total cumulative dose of 1.02 grams (g).
- Iron Sucrose (Type: ACTIVE_COMPARATOR): Participants received iron sucrose based on hemodialysis status. Participants on hemodialysis received either slow IV injection or IV drip infusion of 100 mg of iron sucrose on Day 1 (Baseline) and at the following 9 consecutive hemodialysis sessions for a total cumulative dose of 1.0 g.~Participants not on dialysis received either slow IV injection or IV drip infusion of 200 mg of iron sucrose on Day 1 (Baseline) and at 4 subsequent visits on nonconsecutive days over a 14-day period for a total cumulative dose of 1.0 g.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed locally advanced rectal cancer;~* measurable disease;~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.~Exclusion Criteria:~* prior treatment with bevacizumab;~* prior radiotherapy to pelvic region, or previous cytotoxic chemotherapy;~* previous history of malignancy (other than basal and squamous cell cancer of the skin, or in situ cancer of the cervix);~* history or evidence of central nervous system (CNS) disease;~* clinically significant cardiovascular disease;~* chronic treatment with high dose aspirin (more than \[\>\] 325 milligrams per day \[mg/day\]) or non-steroidal anti-inflammatory drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) (Type: EXPERIMENTAL): In this arm, participants will undergo 3 phases of treatment. During the Phase 1, participants will receive induction chemotherapy with 6 two-week cycles of bevacizumab + Folfox-4 (5-FU + oxaliplatin + folinic acid) for 12 weeks followed by a treatment-free interval of 3 to 4 weeks. The Phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (intravenous \[IV\] infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy \[5-FU + radiotherapy\], with administration of bevacizumab every two weeks \[Cycles 1, 3 and 5\]) followed by a treatment-free interval of 6 to 8 weeks. The Phase 3 will be surgery involving a radical rectal excision using the total mesorectal excision (TME) technique.
- Arm B (Bevacizumab, Chemoradiotherapy) (Type: EXPERIMENTAL): In this arm, participants will receive the Phase 2 and Phase 3 treatments only. The phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (IV infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy \[5-FU + radiotherapy\], with administration of bevacizumab every two weeks \[Cycles 1, 3 and 5\]) followed by a treatment-free interval of 6 to 8 weeks. The phase 3 will be surgery involving a radical rectal excision using the TME technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risk Assessment Model for Ischemic Stroke Endpoint Events

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~(1) Meeting diagnostic criteria of ischemic stroke; (2) Meeting large-artery atherosclerosis or small-artery occlusion subtypes of ischemic stroke according to TOAST (The Trial of Org 10172 in Acute Stroke Treatment) classification \[29\]; (3) In the first 2 weeks of the first onset should account for no less than 50% of all the included cases; (4) 38-80 years of age; (5) Willing to respond truthfully and timely to researcher queries after recruitment, able to cooperate with data and sample collection during follow-ups; (6) Willing to sign informed consent.~Exclusion Criteria:~(1) Meeting diagnostic criteria of transient ischemic attack (TIA), hemorrhagic stroke, or mixed stroke; (2) Meeting cardioembolism, other determined or undetermined etiology subtypes of ischemic stroke according to TOAST classification \[29\]; (3) Unable to participate in data or sample collection for any reason.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Exposure group (Type: None): The exposure group was the patients who were treated with Qilong capsules (QLC). The willingness of the patients and the objective judgment of the clinician were comprehensively considered to decide whether to use QLC for intervention. Patients who chose to use QLC for intervention would take it immediately after being deemed eligible for enrollment. The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks. QLC was produced by Jining Huaneng Pharmaceutical Factory Co., Ltd. All participants in the exposure groups received the standard level of CT provided by clinicians according to the clinical diagnosis and treatment guidelines for IS, including antiplatelet aggregation drugs, antihypertensive drugs, hypoglycemic drugs, and lipid-lowering drugs.
- Non-exposure group (Type: None): The non-exposure group was the patients who did not take QLC. All participants in the non-exposure groups received the standard level of CT provided by clinicians according to the clinical diagnosis and treatment guidelines for IS, including antiplatelet aggregation drugs, antihypertensive drugs, hypoglycemic drugs, and lipid-lowering drugs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lorlatinib Renal Impairment Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects of non-childbearing potential~* Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb)~* Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study~* Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.~* Demonstrate stable renal function~Exclusion Criteria:~* Renal allograft recipients~* Any condition possibly affecting drug absorption (eg, gastrectomy)~* A positive urine drug test~* History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects (1 drink = 5 ounces \[150 mL\] of wine or 12 ounces \[360 mL\] of beer or 1.5 ounces \[45 mL\] of hard liquor) within 6 months before screening.~* Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product (whichever is longer).~* Screening supine triplicate 12 lead ECG demonstrating a corrected QT (QTc) interval \>450 msec or a QRS interval \>120 msec~* Second-degree or third-degree AV block (unless paced) or baseline PR interval \>180 msec at any time prior to dosing of study treatment.~* Abnormalities in clinical laboratory tests at screening~* Pregnant or breastfeeding female subjects~* History of HIV, Hepatitis B, Hepatitis C, HIT, sensitivity to heparin~* Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Mild (Type: EXPERIMENTAL): Mild renal impairment
- Moderate (Type: EXPERIMENTAL): Moderate renal impairment
- Severe (Type: EXPERIMENTAL): Severe renal impairment
- Normal (Type: OTHER): Normal renal function

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants admitted to NICU ≤ 32 weeks gestation at birth~* Birth weight less than 1500 g~* Less than 72 hours of life at time of enrolment~* Diagnosed as IVH by head ultrasound~* Written informed consent of parent or guardian~Exclusion Criteria:~* Genetic metabolic diseases~* Congenital abnormalities~* Polycythaemia (Hct \> 65%) within first 24 hours of life~* Thrombocytopenia (platelets \< 50K cells/microL) within first 24 hours of life~* Unstable vital signs (such as respiration and circulation failure)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Erythropoietin (Type: EXPERIMENTAL): EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Centre Configuration, melted configured with saline to 1ml/kg solution.
- Normal saline (Type: PLACEBO_COMPARATOR): Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.~* 18 to 85 years of age (inclusive).~* If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse).~* Negative urine pregnancy test at screening, if applicable.~* In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study.~Exclusion Criteria:~* Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.~* Subjects with ongoing severe, acute inflammatory bowel disease.~* Subjects who had previous significant gastrointestinal surgeries.~* Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.~* Subjects with uncontrolled hypertension (systolic blood pressure \> 170 mmHg and diastolic blood pressure \> 100 mmHg).~* Subjects with severe renal insufficiency (GFR \< 30 mL/min/1.73m2).~* Subjects with known severe hepatic insufficiency (Child Pugh C).~* Subjects with cardiac insufficiency (NYHA Functional Classifications 3 or 4).~* Subjects undergoing insulin therapy for any indication.~* Subjects with impaired consciousness that predisposes them to pulmonary aspiration.~* Subjects undergoing colonoscopy for foreign body removal and/or decompression.~* Subjects who are pregnant or lactating, or intending to become pregnant during the study.~* Subjects of childbearing potential who refuse a pregnancy test.~* Subjects allergic to any preparation components.~* Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.~* Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.~* Subjects who withdraw consent before completion of Visit 1 procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- BLI4900 (Type: EXPERIMENTAL): BLI4900 Bowel Preparation
- PEG Control (Type: ACTIVE_COMPARATOR): Polyethylene glycol-based bowel preparation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between 50 and 85 years of age with a diagnosis of probable Alzheimers Disease,~* Baseline Mini-Mental State Examination (MMSE) score 10-24 inclusive,~* A primary caregiver willing to accept responsibility for supervising treatment, assessing the patient's condition throughout the study, and for providing input into efficacy assessments.~* For double blind only: Meet the decline criteria of functional (as assessed by the investigator) and cognitive (assessed by a 1 point reduction in Mini-Mental State Examination) score between visits or a 3 point reduction from baseline) decline at weeks 23, 36 or 48.~Exclusion Criteria:~* Presence of an advanced, severe, progressive, or unstable disease of any type that could interfere with efficacy and safety assessments or put the patient at particular risk,~* Any medical or neurological condition other than Alzheimers Disease that could explain the patient's dementia,~* A diagnosis of probable or possible vascular dementia,~* A current diagnosis of unsuccessfully-treated depression, or any other mental disorder that may interfere with the evaluation of the patient's response to study medication,~* A history or current diagnosis of cerebrovascular disease (e.g. stroke),~* A current diagnosis of severe or unstable cardiovascular disease (e.g. unstable coronary artery disease).~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Open label: Rivastigmine (5 cm^2 / 10 cm^2) (Type: EXPERIMENTAL): Rivastigmine 5 cm\^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm\^2 transdermal patch once a day from week 4 to week 24, 36 or 48.
- Double blind: Rivastigmine (10 cm^2) (Type: EXPERIMENTAL): Rivastigmine transdermal patch 10 cm\^2 and placebo to rivastigmine 15 cm\^2 once daily for 48 weeks during the double blind period.
- Double blind: Rivastigmine (15 cm^2) (Type: EXPERIMENTAL): Rivastigmine transdermal patch 15 cm\^2 and placebo to rivastigmine 10 cm\^2 once daily for 48 weeks during double blind period.
- Extended open label Rivastigmine (10 cm^2) (Type: EXPERIMENTAL): Rivastigmine 10 cm\^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Letrozole as a Treatment of Endometrial Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium~* Post menopausal status must be demonstrated~* Signed informed consent~Exclusion Criteria:~* FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the endometrium~* Younger than 40 or postmenopausal status not established~* Pregnant or breastfeeding

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Letrozole (Type: EXPERIMENTAL): letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy.
- control (Type: NO_INTERVENTION): no treatemtn prior to hysterectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subject over 18 years of age~* having a neurogenic bladder with automatic catheter and pharmacologic disconnection of the detrusor muscle~* having at least 4 symptomatic UTIs per year with bacterial sensitivity to the chosen antibiotics~* having given full consent to participate in the study~* being the recipient of social security benefits~Exclusion Criteria:~* known allergy or hypersensitivity to useful antibiotics (to which the bacterium or bacteria are sensitive) or to one of their components~* other contraindication in the administering of useful antibiotics~* urinary volume flow \>500 ml during automatic catheter~* different urinary drainage method than automatic catheter~* occurrence of stones in the urinary tract~* infection due to endo urinary material (urinary prosthesis, ureteral stent)~* creatinine clearance \<60 ml/min~* patient under guardianship~* women who are pregnant, nursing, or who may become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Weekly Oral Cyclic Antibiotic programme (Type: EXPERIMENTAL): None
- Classic care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with glaucoma or ocular hypertension~Exclusion Criteria:~* Other eye conditions~* Poor vision~* Recent eye surgery~* Use of contact lenses~* Nursing or pregnant women~* Use of some other selected medications~* Drug or alcohol abuse~* Asthma~* Slow heart beat~* Allergy or previous reaction to study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete